SenzaGen AB (SENZA.ST)

SEK 7.0

(0.0%)

Operating Expenses Summary of SenzaGen AB

SenzaGen AB's latest annual operating expenses in 2023 was 49.67 Million SEK , up 4.52% from previous year.
SenzaGen AB's latest quarterly operating expenses in 2024 Q1 was 11.76 Million SEK , down -51.75% from previous quarter.
SenzaGen AB reported a annual operating expenses of 47.52 Million SEK in annual operating expenses 2022, up 15.96% from previous year.
SenzaGen AB reported a annual operating expenses of 40.98 Million SEK in annual operating expenses 2021, up 36.39% from previous year.
SenzaGen AB reported a quarterly operating expenses of 11.76 Million SEK for 2024 Q1, down -51.75% from previous quarter.
SenzaGen AB reported a quarterly operating expenses of 24.38 Million SEK for 2023 Q4, up 70.4% from previous quarter.

Annual Operating Expenses Chart of SenzaGen AB (2023 - 2014)

Historical Annual Operating Expenses of SenzaGen AB (2023 - 2014)

Year	Operating Expenses	Operating Expenses Growth
2023	49.67 Million SEK	4.52%
2022	47.52 Million SEK	15.96%
2021	40.98 Million SEK	36.39%
2020	30.05 Million SEK	-27.46%
2019	41.42 Million SEK	38.15%
2018	29.98 Million SEK	11.41%
2017	26.91 Million SEK	164.89%
2016	10.16 Million SEK	137.63%
2015	4.27 Million SEK	6687.3%
2014	63 Thousand SEK	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	15.83 Million SEK	34.53%
2024 Q1	11.76 Million SEK	-51.75%
2023 Q4	24.38 Million SEK	70.4%
2023 Q2	25.28 Million SEK	90.11%
2023 FY	49.67 Million SEK	4.52%
2023 Q1	13.29 Million SEK	-43.79%
2023 Q3	14.31 Million SEK	-43.39%
2022 Q2	24.35 Million SEK	84.85%
2022 Q4	23.65 Million SEK	81.48%
2022 FY	47.52 Million SEK	15.96%
2022 Q1	13.17 Million SEK	-44.4%
2022 Q3	13.03 Million SEK	-46.47%
2021 Q2	16.96 Million SEK	100.54%
2021 FY	40.98 Million SEK	36.39%
2021 Q4	23.69 Million SEK	97.79%
2021 Q3	11.97 Million SEK	-29.38%
2021 Q1	8.45 Million SEK	-47.45%
2020 Q1	7.87 Million SEK	-32.01%
2020 FY	30.05 Million SEK	-27.46%
2020 Q4	16.09 Million SEK	88.62%
2020 Q3	8.53 Million SEK	-45.74%
2020 Q2	15.72 Million SEK	99.67%
2019 Q3	11.58 Million SEK	44.23%
2019 Q2	8.03 Million SEK	0.0%
2019 Q1	8.03 Million SEK	-3.7%
2019 FY	41.42 Million SEK	38.15%
2019 Q4	11.58 Million SEK	0.0%
2018 FY	29.98 Million SEK	11.41%
2018 Q1	6.65 Million SEK	-5.08%
2018 Q2	6.65 Million SEK	0.0%
2018 Q3	8.34 Million SEK	25.39%
2018 Q4	8.34 Million SEK	0.0%
2017 Q2	6.46 Million SEK	0.0%
2017 FY	26.91 Million SEK	164.89%
2017 Q3	7 Million SEK	8.41%
2017 Q1	6.46 Million SEK	92.97%
2017 Q4	7 Million SEK	0.0%
2016 FY	10.16 Million SEK	137.63%
2016 Q3	3.35 Million SEK	15.62%
2016 Q2	2.89 Million SEK	0.0%
2016 Q1	2.89 Million SEK	0.0%
2016 Q4	3.35 Million SEK	0.0%
2015 FY	4.27 Million SEK	6687.3%
2014 FY	63 Thousand SEK	0.0%

Peer Operating Expenses Comparison of SenzaGen AB

Name	Operating Expenses	Operating Expenses Difference
AroCell AB (publ)	57.68 Million SEK	13.886%
Devyser Diagnostics AB (publ)	204.6 Million SEK	75.722%
Immunovia AB (publ)	291.35 Million SEK	82.951%
Prostatype Genomics AB (publ)	3.22 Million SEK	-1440.217%
Spermosens AB	10.72 Million SEK	-363.142%